Portfolio

  • InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer

    April 4, 2017

    InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer Signals next phase of expansion with cardiologists and electrophysiologists to improve the quality of patient care, reduce costs, and maximize reimbursement. Press Release

    Read More
  • Herantis Pharma’s clinical study with Lymfactin advances to high dose level

    March 6, 2017

    Herantis Pharma’s clinical study with Lymfactin advances to high dose level Herantis Pharma PlcCompany release 6 March 2017 at 10:00 am Herantis Pharma Plc’s (“Herantis”) clinical study with the company’s innovative gene therapy investigational product Lymfactin® for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety. A Data Monitoring Committee of independent experts recommended proceeding to high dose treatments after assessing safety data on the previously treated patients. Following the recommendation, the first high

    Read More
  • miRagen Therapeutics Completes merger with Signal Genetics and Concurrent $40.7M Equity Financing

    February 13, 2017

    BOULDER, CO – February 13, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced the completion of its merger with Signal Genetics, Inc., effective February 13, 2017.  Concurrent with the closing of the merger, miRagen received gross proceeds of $40.7 million in new equity investment from a combination of current and new miRagen investors, including Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd.,

    Read More
  • Nido Surgical Raises $1.3M Series A Led By Broadview Ventures

    February 7, 2017

    Nido Surgical Raises $1.3M Series A Led By Broadview Ventures BOSTON, Feb. 7, 2017 --Nido Surgical, Inc., a development-stage medical device company focused on creating innovative solutions for beating heart surgery, has raised $1.3 million in a Series A financing led by Broadview Ventures (Boston, MA). The funds will be used to finance the development and First-In-Man studies of Nido Surgical' platform product, the CardioPort™. Nido Surgical has also received a $1.4 million Small Business Technology Transfer (STTR) grant from the National Institutes of Health to support this work.

    Read More
  • Remedy Granted Orphan Drug Designation

    January 16, 2017

    Remedy Pharmaceuticals’ CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke NEW YORK, New York, January 17, 2017 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatments to people affected by central nervous system related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational drug, CIRARA, for treatment of severe cerebral edema in patients with acute ischemic stroke. Link to Press Release

    Read More
  • miRagen Therapeutics & Signal Genetics Sign Merger Agreement

    October 31, 2016

    October 31, 2016 - miRagen Therapeutics and Signal Genetics Sign Merger Agreement Signal Genetics, Inc. (Nasdaq: SGNL) (“Signal”) and Miragen Therapeutics, Inc. (“miRagen”), a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of miRagen are currently estimated to become holders of approximately 96% of Signal’s outstanding common stock on a fully-diluted basis. The proposed merger remains subject to certain conditions, including approval by Signal’s and miRagen’s stockholders. Press Re

    Read More
  • InfoBionic receives Frost & Sullivan award for Innovation

    July 27, 2016

    July 27, 2016  Based on its recent analysis of the arrhythmia detection and monitoring market, Frost & Sullivan recognizes InfoBionic with the 2016 North America Frost & Sullivan Award for New Product Innovation. InfoBionic’s MoMe® Kardia system plugs the gaps in traditional cardiac arrhythmia detection devices by optimizing its clinical utility for patients and physicians alike. MoMe Kardia is a wireless remote monitoring system that aids in the detection, management, and diagnosis of cardiac arrhythmias.   Press Release

    Read More
  • Remedy Pharmaceuticals Receives FDA Fast Track Designation

    June 8, 2016

    June 08, 2016 - Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA™ Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug, CIRARA, for the treatment of Large Hemispheric Infarctions (LHI). Press Release

    Read More
  • GI Windows Announces Data from FIH Study

    May 24, 2016

    May 24, 2016 GI Windows, a clinical-stage medical device company, today announced the presentation of six-month results of the first-ever clinical study evaluating the endoscopic creation of a dual-path enteral diversion using the company’s Incision-less Anastomosis System (IAS) at Digestive Disease Week® 2016 (DDW), in San Diego, Calif. The data support the safety and efficacy of GI Windows’ IAS as a treatment option for Type 2 diabetes in obese patients. Press Release

    Read More
  • Remedy Pharmaceuticals Presents at American Academy of Neurology Meeting

    April 12, 2016

    April 12, 2016 - Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that results from its Phase 2 trial of CIRARA™ for preventing edema (brain swelling) in large hemispheric infarctions will be presented during two oral presentations at the 68th annual American Academy of Neurology (

    Read More